GlaxoSmithKline ( GSK ) has reported a robust performance for the fiscal year 2024, showcasing significant growth in its specialty medicines portfolio and setting an optimistic outlook for the future. Key Financial Highlights: Total Sales: £31.4 billion, marking a 7% increase at constant exchange rates (CER). Specialty Medicines: Experienced a 19% growth, driven by: HIV Treatments: Sales up by 13%. Oncology Segment: Nearly doubled with a 98% increase. Respiratory and Immunology: Grew by 13%. Vaccines: Faced a 4% decline, with Shingrix increasing by 1% and Arexvy decreasing by 51%. General Medicines: Saw a 6% rise, with Trelegy leading at a 27% growth.
A periodical exploring the art of investing, financial knowledge, and the stories that shape a meaningful life.